T. Rowe Price Associates’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $194K | Buy |
56,821
+3,484
| +7% | +$11.9K | ﹤0.01% | 2725 |
|
|
2025
Q1 | $214K | Buy |
53,337
+6,148
| +13% | +$24.7K | ﹤0.01% | 2599 |
|
|
2024
Q4 | $307K | Buy |
47,189
+7,686
| +19% | +$50K | ﹤0.01% | 2488 |
|
|
2024
Q3 | $219K | Buy |
39,503
+1,176
| +3% | +$6.52K | ﹤0.01% | 2620 |
|
|
2024
Q2 | $214K | Buy |
38,327
+3,662
| +11% | +$20.4K | ﹤0.01% | 2567 |
|
|
2024
Q1 | $233K | Buy |
34,665
+3,987
| +13% | +$26.8K | ﹤0.01% | 2541 |
|
|
2023
Q4 | $280K | Buy |
30,678
+2,630
| +9% | +$24K | ﹤0.01% | 2408 |
|
|
2023
Q3 | $155K | Buy |
28,048
+3,304
| +13% | +$18.3K | ﹤0.01% | 2565 |
|
|
2023
Q2 | $212K | Buy |
24,744
+3,210
| +15% | +$27.5K | ﹤0.01% | 2505 |
|
|
2023
Q1 | $198K | Buy |
21,534
+1,558
| +8% | +$14.3K | ﹤0.01% | 2533 |
|
|
2022
Q4 | $204K | Buy |
19,976
+1,573
| +9% | +$16.1K | ﹤0.01% | 2525 |
|
|
2022
Q3 | $271K | Buy |
18,403
+7,508
| +69% | +$111K | ﹤0.01% | 2420 |
|
|
2022
Q2 | $117K | Buy |
+10,895
| New | +$117K | ﹤0.01% | 2718 |
|